| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
iRadimed (NASDAQ:IRMD) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.90...